IP Library › Granted Patent US 9,193,749
Granted Patent B2
US 9,193,749 · App. 13/767,478 · Granted Nov 24, 2015

Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors

Inventors: Robert Deziel (Mount-Royal, CA); Silvana Leit (Kirkland, CA); Patrick Beaulieu (Laval, CA); Yves Andre Chantigny (Pincourt, CA); John Mancuso (Vaudreuil, CA); Pierre Tessier (Hawkesbury, CA); Gideon Shapiro (Gainesville, FL); Richard Chesworth (Boston, MA); David Smil (Montreal, CA)
Assignees: Forum Pharmaceuticals, Inc.; MethylGene, Inc.
C07H13/10C07D209/02C07D209/08C07D209/52C07D209/94C07D221/12C07D223/16C07D223/20C07D223/22C07D223/26C07D223/28C07D225/08C07D239/28C07D239/34C07D239/42C07D243/24C07D243/38C07D265/38C07D267/14C07D267/18C07D267/20C07D279/22C07D279/26C07D281/16C07D285/36C07D291/08C07D295/155C07D313/12C07D401/14C07D403/04C07D403/14C07D413/06C07D413/12C07D471/04C07D471/08C07D487/04C07D487/08C07D487/14C07D491/08C07D495/04C07D498/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,749
App. No.
13/767,478
Granted
Nov 24, 2015
Kind
B2
Abstract

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

Claims (4)

1. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with a pharmaceutical composition comprising:

i) (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof; and

ii) a pharmaceutically acceptable carrier, excipient, or diluent.

2. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof.

Assignments (4)
SECURITY INTEREST Recorded Jul 5, 2016
From: FORUM PHARMACEUTICALS INC.
To: FMR LLC
Reel/Frame 039254/0828 →
CHANGE OF NAME Recorded Oct 29, 2014
From: ENVIVO PHARMACEUTICALS, INC.
To: FORUM PHARMACEUTICALS, INC.
Reel/Frame 034086/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2014
From: SHAPIRO, GIDEON; CHESWORTH, RICHARD
To: ENVIVO PHARMACEUTICALS
Reel/Frame 032356/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2014
From: DEZIEL, ROBERT; LEIT, SILVANNA; BEAULIEU, PATRICK; CHANTIGNY, YVES ANDRE; MANCUSO, JOHN; TESSIER, PIERRE; SMIL, DAVID
To: METHYLGENE INC.
Reel/Frame 032356/0479 →
Continuity (4)
Division 11925151 · Oct 26, 2007
Provisional Application 60863347 · Oct 28, 2006
Provisional Application 60884287 · Jan 10, 2007
Related Publication 20140011988A1 · Jan 9, 2014